Genomics

Quintara Biosciences launches AmpValue, a $4.99 overnight sequencing service set to disrupt biotech by making advanced, full-length data accessible to all.

A new service from Alida Biosciences simultaneously reads three key RNA modifications, opening a new frontier in disease diagnostics and biological research.

Atelerix's revolutionary hydrogel eliminates the need for cold chain logistics, partnering with JH Health to unlock the booming Saudi biotech market.

As scientific innovation in oncology accelerates, a new bottleneck emerges: bringing discoveries to market. Specialized firms are now crucial guides.

The Jackson Laboratory appoints Steven Holstein to bridge science and capital, supercharging its new integrated platform for developing breakthrough therapies.

A single-dose therapy wiped out aggressive glioblastoma tumors in a landmark pre-clinical study, paving the way for human trials in 2026.

AIRNA has dosed the first patient with AIR-001, an RNA-editing drug that could treat both the lung and liver damage of a devastating genetic disease.

TriNetX's acquisition of Zetta Genomics' XetaBase platform promises to accelerate research by integrating genomic and clinical data on a global scale.

A new clinical trial uses multi-ancestry genetic risk scores to see if knowing your DNA can motivate you to prevent heart disease. Here's how it works.

Formerly TT Capital Partners, the independent firm's new identity follows a major fundraise, sharpening its focus on healthcare IT in a competitive market.

For years, doctors dismissed her children's illness. One genetic test changed everything, revealing a truth hidden in their DNA and a flawed system.

A $2.9M investment funds five new projects using DNA and AI to clean up oil sands, secure hydrogen energy, and build a more sustainable future for Alberta.

Agena Bioscience's new test helps labs align with updated ACMG recommendations for cystic fibrosis, aiming for more equitable and efficient carrier screening.

A new partnership between Takara Bio and Hamilton promises to revolutionize RNA-seq, making high-throughput genomic analysis faster and more reliable.

After a massive breach exposed sensitive genetic data, 23andMe's Canadian settlement is final. Learn what went wrong and how to claim your share.

A US firm is bringing embryo screening for chronic diseases to major IVF networks, sparking debate on the future of family planning and genetic health.

With CE Mark approval, Countable Labs brings single-molecule counting PCR to Europe, promising unprecedented precision for gene therapy and diagnostics.

A new platform uses AI to turn complex genetic and lifestyle data into an immediate, actionable cancer prevention plan, shifting the paradigm of care.

New cardiology guidelines now include DNA risk scores, a move poised to revolutionize prevention and spot hidden threats before they strike.

SAB Biotherapeutics' public offering fuels late-stage trials for its promising T1D drug, SAB-142, aiming to change the treatment landscape.